Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.
Also called NCT04120753
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 106 participants
- Registry
-
NCT04120753
-
- Other papers using this trial's data
- Efficacy and Safety of a Single-Pill Triple Combination of Olmesartan, Amlodipine, and Rosuvastatin in Hypertensive Patients with Low-to-Moderate Cardiovascular Risk: A Multicenter, Randomized, Open-Label, Active-Control, Phase IV Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04120753. Randomized; no masking; primary purpose treatment. Start 2019-08-26 (actual); primary completion 2021-07-06 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab
- Condition
- Hypertension
- Condition
- Dyslipidemias
- Intervention (Drug)
- OLOMAX 20/5/5mg
- Intervention (Drug)
- OLOMAX 20/5/10mg
- Intervention (Drug)
- Olmesartan 20 mg/Amlodipine 5 mg
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.
Record details
- Record id
cardio:ct-nct04120753- Content hash
8667956ccfd4c235cb6095c9f26dd3a240f4e5a9673599d4d37a05a1a55f6deb